Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

Multicenter Trial Using Multi-dose Rituximab as Induction and Desensitization Therapy for Patients on the Waiting List for Kidney Transplant With a Positive Donor Specific Crossmatch to a Living Donor

This is a study of patients who have a high risk of kidney rejection before kidney transplant. The hypothesis is that treatment with a medication called rituximab will make it possible for them to receive a kidney transplant from a donor who previously did not present a good match.

Inclusion Criteria:

• Active status on a kidney transplant waiting list with positive cross match against a living donor

Exclusion Criteria:

• Receipt of a live vaccine within 4 weeks prior to randomization
• Previous Treatment with Rituximab